Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242109 | 0.98 | ALOX5 (0.36) | ALOX5EPHX1HSD11B1ALDH1A1ADH1A | |
| SCHEMBL6827765 | 0.84 | ALOX5 (0.45) | ALOX5EPHX1HSD11B1FDPSADH1A | |
| SCHEMBL1957147 | 0.83 | ALOX5 (0.41) | ALOX5EPHX1HSD11B1ALDH1A1KDM4E | |
| SCHEMBL22729195 | 0.82 | ALOX5 (0.43) | ALOX5EPHX1HSD11B1FDPSADH1A | |
| SCHEMBL28496043 | 0.77 | ALOX5 (0.39) | ALOX5EPHX1HSD11B1ALDH1A1LMNA | |
| SCHEMBL3069635 | 0.77 | ALOX5 (0.39) | ALOX5EPHX1HSD11B1FDPSADH1A | |
| SCHEMBL3083216 | 0.75 | CES2 (0.41) | ALOX5EPHX1HSD11B1ALDH1A1RECQL | |
| SCHEMBL7404178 | 0.73 | EPHX1 (0.38) | ALOX5EPHX1FDPSADH1ACES2 | |
| SCHEMBL7404175 | 0.73 | EPHX1 (0.38) | ALOX5EPHX1FDPSADH1ACES2 | |
| SCHEMBL6237975 | 0.73 | OPRK1 (0.37) | ALOX5EPHX1ADH1ASMN1; SMN2ADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | claimed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| CN-100398102-C | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2008-07-02 | — | — | CN | disclosed |
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1681488-A | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1537866-A1 | DRUG FOR KIDNEY FAILURE CONTAINING OXALURIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| CN-1197572-C | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-20 | — | — | CN | disclosed |
| CN-1143674-C | Refractory vasculitis therapeutic preparation | �ձ���ҩ��ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| CN-1371687-A | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2002-10-02 | — | — | CN | disclosed |
| CN-1253775-A | Refractory vasculitis therapeutic preparation | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-05-24 | — | — | CN | disclosed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4708954-A | DIABETES-ORAL ADMINISTRATION | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | OAT, OTC, OGFRL1 | ALOX5 860/4885EPHX1 1631/4885HSD11B1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.